What Is a Carcinoid Tumor of the Small Intestine?

Slow-growing neuroendocrine masses arise from the hormone-producing enterochromaffin cells lining the bowel, and they most frequently appear in the ileum. These tumors release serotonin and other vasoactive substances, which is why they are classified as neuroendocrine tumors (NETs). Unlike the more familiar gut adenocarcinomas, they can sit quietly for years before causing symptoms, and many are first discovered during imaging or surgery done for an unrelated reason.

What follows covers how these tumors form, how they differ from other intestinal cancers, the warning signs worth tracking, the diagnostic workup, treatment pathways, and what to bring to your care team next.

The Basics of Small Intestine Carcinoid Tumors

Neuroendocrine tumors, often shortened to NETs, form the broader family to which small intestinal carcinoid tumors belong. They spring from enterochromaffin cells scattered along the inner lining of the bowel, cells whose normal job is to release hormones like serotonin in response to digestion. Because those cells sit deep in the wall rather than on the surface, the tumors tend to grow slowly and push outward into the mesentery, the fan of tissue that carries blood vessels to the gut.

The ileum, the final and longest stretch of the small intestine, accounts for the majority of cases. The duodenum and jejunum are far less common sites. A defining feature is how quietly these tumors grow. Many people carry a small ileal carcinoid for years with no symptoms at all, and the tumor only surfaces when a surgeon discovers it during an appendectomy or an imaging scan ordered for something else.

Because they grow from hormone-producing cells instead of the surface lining, these tumors behave differently from typical intestinal adenocarcinomas. They spread through the lymphatic system, often pulling mesentery into a fibrous mass that can kink the bowel, and they can secrete bioactive substances once they reach the liver.

Because their behavior diverges from adenocarcinomas and lymphomas, comparing them side-by-side clarifies why prognosis and treatment differ so sharply.

Key facts about how these tumors behave

• ▸Cell of origin: Enterochromaffin cells, the serotonin-storing cells of the diffuse neuroendocrine system.
• ▸Most common site: The ileum, especially the distal segment near the ileocecal valve.
• ▸Growth pattern: Slow, with a tendency to trigger dense fibrotic reactions in nearby mesentery.
• ▸Discovery pattern: Frequently incidental, found during workup for abdominal pain, anemia, or unrelated surgery.

How Carcinoid Tumors Compare With Other Intestinal Cancers

The contrast with typical bowel adenocarcinoma matters because treatment, staging, and prognosis follow different rules. Adenocarcinomas arise from the surface gland cells that line the gut, grow quickly, and are usually staged with the classic TNM system. Carcinoid tumors come from deeper hormone-producing cells, advance more slowly, and are graded by how fast their cells divide.

Pathologists measure two things to grade one of these tumors: the Ki-67 index, a percentage of cells actively dividing, and the mitotic count, or how many cells are caught in the act of dividing under the microscope. Together those numbers place a tumor into Grade 1, Grade 2, or Grade 3 under the WHO classification of neuroendocrine tumors. Most small intestine carcinoids are well-differentiated Grade 1 tumors with Ki-67 values below 3 percent.

Small intestine carcinoids account for roughly one third of all gastrointestinal neuroendocrine tumors, making them the single largest group within that family even though they remain uncommon in the wider population.

Symptoms, Carcinoid Syndrome, and When to Suspect a Tumor

The early clues are vague enough that they get blamed on something else for months. Intermittent crampy abdominal pain, bloating, and bouts of nausea are the most common early signs of a small intestinal carcinoid tumor. As the tumor grows, it can pull the mesentery into a fibrous tangle that narrows the bowel, producing episodes of partial obstruction with distension, vomiting, and loud bowel sounds.

Carcinoid syndrome small intestine is a separate, more dramatic pattern that appears when liver metastases allow tumor-derived serotonin to escape into the systemic circulation. The liver normally filters these substances before they reach the rest of the body. Once the liver is involved, the hormone bypasses that filter, and flushing, watery diarrhea, and wheezing can develop.

The warning pattern worth flagging

• ▸Flushing: Warm reddening of the face and upper chest, often triggered by stress, alcohol, or certain foods.
• ▸Secretory diarrhea: Loose, watery stools that persist even when food intake changes.
• ▸Wheezing or shortness of breath: Bronchospasm from circulating vasoactive substances.
• ▸Right-sided heart changes: Long-standing serotonin exposure can thicken the tricuspid and pulmonary valves, a complication known as carcinoid heart disease.

Because these symptoms overlap with irritable bowel syndrome, food intolerance, and anxiety, a pattern that keeps returning or worsens over months deserves a closer look. Guidance from the National Cancer Institute notes that many carcinoid tumors are diagnosed only after the disease has already reached the liver, which is one reason persistent flushing and diarrhea together warrant a conversation with a gastroenterologist.

That diagnostic delay is exactly why understanding how these tumors are found and classified matters before symptoms drive the workup.

How Doctors Diagnose and Stage Small Bowel Carcinoids

Diagnosis usually starts with two biochemical tests that flag neuroendocrine activity: a chromogranin A blood level and a 24-hour urinary 5-HIAA collection, where 5-HIAA is the breakdown product of serotonin. Chromogranin A is a general marker of neuroendocrine cell activity. The 5-HIAA urine test is more specific, but it requires avoiding certain foods and medications that can skew the result.

Imaging comes next to locate the tumor and check for spread. A multiphase CT or MRI of the abdomen and pelvis maps the primary lesion and any liver involvement. A DOTATATE scan, also called a somatostatin receptor scintigraphy or octreotide scan, lights up tumors that carry somatostatin receptors on their surface, which most well-differentiated carcinoids do.

Standard endoscopy often misses ileal lesions because the scope cannot reach that far. Capsule endoscopy and double-balloon enteroscopy were developed for exactly this reason. A biopsy of the tumor, or sometimes of liver metastases, allows the pathologist to measure Ki-67 and the mitotic index, which together set the grade and guide prognosis. This combination is the backbone of small intestinal neuroendocrine tumor diagnosis.

Diagnostic checklist your team may follow

• ▸Biochemical screen: Chromogranin A blood test plus 24-hour urinary 5-HIAA.
• ▸Cross-sectional imaging: CT or MRI of the abdomen and pelvis to find the primary and assess the liver.
• ▸Receptor imaging: DOTATATE PET/CT to detect somatostatin-receptor-positive disease throughout the body.
• ▸Deep bowel visualization: Capsule endoscopy or double-balloon enteroscopy to reach the ileum.
• ▸Tissue confirmation: Biopsy with Ki-67 and mitotic count for grading.

“Ask whether the pathology report includes both the Ki-67 percentage and the mitotic count per 10 high-power fields. Those two numbers, not size alone, drive the grade and most treatment decisions.

Treatment Pathways From Surgery to Long-Term Control

For localized disease, surgery is the cornerstone. Surgical resection of the primary tumor along with any involved mesentery and draining lymph nodes offers the best chance of cure and prevents the fibrotic kinking that causes obstruction. Even when liver metastases are present, removing the primary tumor often improves symptoms and may extend survival.

Somatostatin analogs like octreotide and lanreotide mimic a natural hormone that blocks the release of serotonin and other peptides. They are the backbone of symptom control for carcinoid syndrome and also slow tumor growth in many well-differentiated tumors. Patients on these injections usually notice a reduction in flushing and diarrhea within weeks.

When liver metastases are the main problem, liver-directed therapies step in. Options include hepatic artery embolization, which starves metastases of blood flow, radiofrequency ablation of small lesions, and peptide receptor radionuclide therapy (PRRT), which delivers targeted radiation directly to somatostatin-receptor-positive tumors. Decisions about which approach fits your situation depend on tumor burden, liver function, and grade. Together these options define ileal carcinoid tumor treatment in 2026.

What a typical care pathway looks like

• ▸Localized tumor: Surgical resection with mesenteric lymph node clearance.
• ▸Hormone-driven symptoms: Somatostatin analog therapy to control flushing and diarrhea.
• ▸Liver-dominant metastases: Liver-directed therapy, PRRT, or both, often combined with somatostatin analogs.
• ▸Higher-grade disease: Consideration of systemic options under a NET specialist, tailored to grade and progression rate.
• ▸Surveillance: Multidisciplinary NET teams typically set imaging and biomarker intervals based on grade, stage, and resection completeness.

Work with a multidisciplinary neuroendocrine tumor team for any therapy choice. ENETS guidelines emphasize that grade and stage, not tumor size alone, drive the intensity of treatment and the surveillance schedule.

Treatment choices already shape the surveillance plan, so the prognostic picture follows directly from the pathway a team selects.

Prognosis, Outlook, and Questions to Bring to Your Care Team

Outlook depends heavily on stage at diagnosis, and small intestine neuroendocrine tumor prognosis varies widely along that axis. Five-year survival for localized small intestine carcinoids approaches near 100 percent, while survival drops meaningfully once the liver is involved. Tumor grade shapes that picture too. A Grade 1 tumor with a Ki-67 below 3 percent tends to behave very differently from a Grade 3 tumor with a Ki-67 above 20 percent.

Recurrences can surface years after the initial operation, which is why lifelong follow-up is standard. Serial chromogranin A measurements and periodic imaging track the disease even when symptoms stay quiet. Structured surveillance, rather than reactive care, improves long-term outcomes.

Questions worth raising at your next visit

• ▸Specialist referral: Ask whether a NET-focused center should coordinate your care.
• ▸Biomarker tracking: Confirm how often chromogranin A and urinary 5-HIAA will be measured.
• ▸Imaging cadence: Clarify the schedule for CT, MRI, or DOTATATE scans based on grade and stage.
• ▸Symptom thresholds: Define the specific signs that should prompt an earlier call.

“Bring a written list of every symptom you have had in the last three months, including the dates. Neuroendocrine tumors progress slowly, and a clear timeline often reveals patterns you would otherwise miss.

Bottom Line

Small intestine carcinoid tumors are slow-growing neuroendocrine growths that hide for years behind vague abdominal symptoms or surface only when they trigger carcinoid syndrome after spreading to the liver. Surgery cures most localized cases, somatostatin analogs control hormone-driven symptoms, and modern imaging plus receptor-targeted therapy give metastatic disease more options than ever.

Partnering early with a NET specialist, knowing your grade, and committing to long-term follow-up are the habits that shape the best long-term outcomes.

FAQ